Dapagliflozin plus pioglitazone in T1D
What this study tests
Adjunct metabolic trial adding pioglitazone or placebo after a dapagliflozin lead-in in type 1 diabetes, testing whether the combination improves HbA1c without amplifying ketones. Recruitment has closed; follow-up continues.
Editorial review: .
Registry checked: 2026-09-17. Registry’s own update: 2026-07-29.
Source dates appear in the references where available; this record has no dated citation metadata.
Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence
Evidence at a glance
- Who can enter the study?
- Adults with T1D, HbA1c 7-11%, fasting C-peptide below 0.7 ng/mL and eGFR at least 60 mL/min; see registry for full criteria. Registered eligibility ↗Enrollment criteria describe who may enter. They do not establish who was analyzed or the denominator for a reported result.
- Reported benefit and results
- No results posted. Actual enrolment was 120; the primary-completion date was 15 March 2026, with longer follow-up estimated through December 2027.Read the result sources and their limitations →
- Important harms
- Read the reported results, safety discussion and original sources. A separate harms summary is not available; this does not establish safety.
- Research access and approval
- Study regions: United States, Other regions. A trial listing does not establish product approval or current recruitment at a particular site. Check the study’s current entry requirements.
- What remains uncertain?
- Read the full discussion and original sources for study limitations. Planned endpoints and completion dates are not results.
Research status alone does not establish approval, clinical benefit or local availability.
Primary endpoints
- Decrease in HbA1c
The full picture
This record has no longer discussion. Use the study criteria, reported results and original sources on this page to assess what is known and what remains unresolved.
Sources
- [1]NCT03878459: Dapagliflozin plus pioglitazone in T1D · Trial registry — Registry checked 2026-08-08: ACTIVE_NOT_RECRUITING, actual enrolment 120, actual primary completion 2026-03-15, estimated study completion 2027-12-31; update posted 2026-07-29.